Kristine Slam, MD, FACP, Central Ohio Surgical Associates, addresses the importance of involving patients in decisions regarding their goals for treatment, emphasizing that this involvement is critical to uncover what they value, as well as their short- and long-term goals for treatment.
"Part of the discussion we have with patients is, what are their values? It's really bringing the patient front and center and asking them about their short- and long-term goals, and their fears, because each patient chooses different surgery and different therapy based on that," noted Kristine Slam, MD, Central Ohio Surgical Associates, in an interview from our September 14 Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio.
Transcript
What roles do patient engagement and shared decision-making play in value-based care for breast cancer?
So patient decision-making and patient involvement in decision-making is critical. What I have found over my years is patients have different values and expectations. One of the things that comes to forefront with this is the application of breast radiation for, again, elderly lower-risk women. For years, we told patients a lumpectomy goes with radiation like peanut butter and jelly—you can't do one without the other. We have 2 very-long-term studies that clearly prove in low-risk elderly women, radiation does not make a patient live longer. It lowers the recurrence rate in the breast, but never eliminates it.
So part of the discussion we have with patients is, what are their values? Is their value and is their goal for their therapy living longer? Because if so, radiation is not going to help that. Is their goal to reduce their breast cancer risk as much as possible? If so, radiation might help. It's really bringing the patient front and center and asking them what their short-term and long term goals are, what their fears are, because each patient chooses different surgery and different therapy based on that.
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Polypharmacy Common in Rheumatoid Arthritis, Driving Risk of Serious Drug Interactions
August 13th 2025More than 8 in 10 patients with rheumatoid arthritis were taking 5 or more medications at once, a practice linked to older age, multiple comorbidities, and more than 2000 potential drug-to-drug interactions.
Read More